Literature DB >> 19874270

O-GlcNAc modification and the tauopathies: insights from chemical biology.

Scott A Yuzwa1, David J Vocadlo.   

Abstract

The aggregation of the microtubule-associated protein tau into paired-helical filaments is the defining characteristic of the tauopathies. It has become apparent that the hyperphosphorylation of tau likely plays a role in the aggregation process and thus strategies to reduce tau phosphorylation are generating wide interest. The O-GlcNAc posttranslational modification of tau has been shown to be reciprocal to its phosphorylation; increasing O-GlcNAc leads to reductions in tau phosphorylation. In this mini-review, we highlight the use of chemical compounds as a means of understanding the reciprocal nature of tau phosphorylation and tau O-GlcNAcylation and highlight some recent progress in this area.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874270     DOI: 10.2174/156720509789207967

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  11 in total

Review 1.  Modulation of transcription factor function by O-GlcNAc modification.

Authors:  Sabire Ozcan; Sreenath S Andrali; Jamie E L Cantrell
Journal:  Biochim Biophys Acta       Date:  2010-03-02

Review 2.  O-GlcNAc signaling in cancer metabolism and epigenetics.

Authors:  Jay Prakash Singh; Kaisi Zhang; Jing Wu; Xiaoyong Yang
Journal:  Cancer Lett       Date:  2014-04-24       Impact factor: 8.679

3.  O-GlcNAcylation of AMPA receptor GluA2 is associated with a novel form of long-term depression at hippocampal synapses.

Authors:  Erica W Taylor; Kai Wang; Amy R Nelson; Teruko M Bredemann; Kyle B Fraser; Sarah M Clinton; Rosemary Puckett; Richard B Marchase; John C Chatham; Lori L McMahon
Journal:  J Neurosci       Date:  2014-01-01       Impact factor: 6.167

Review 4.  Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.

Authors:  Ilhan Akan; Stephanie Olivier-Van Stichelen; Michelle R Bond; John A Hanover
Journal:  J Neurochem       Date:  2017-11-20       Impact factor: 5.372

5.  Inhibition of O-GlcNAcase (OGA): A Potential Therapeutic Target to Treat Alzheimer's Disease.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-11-20       Impact factor: 4.345

6.  SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Kevin Mayo; Noah Spiegel; Sarah Bertelsen; Petra Nowotny; Aarti R Shah; Richard Abraham; Paul Hollingworth; Denise Harold; Michael M Owen; Julie Williams; Simon Lovestone; Elaine R Peskind; Ge Li; James B Leverenz; Douglas Galasko; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

Review 7.  Cracking the O-GlcNAc code in metabolism.

Authors:  Hai-Bin Ruan; Jay Prakash Singh; Min-Dian Li; Jing Wu; Xiaoyong Yang
Journal:  Trends Endocrinol Metab       Date:  2013-05-04       Impact factor: 12.015

8.  Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.

Authors:  Stefani N Thomas; Kristen E Funk; Yunhu Wan; Zhongping Liao; Peter Davies; Jeff Kuret; Austin J Yang
Journal:  Acta Neuropathol       Date:  2011-10-28       Impact factor: 17.088

9.  REM Sleep Deprivation Impairs Learning and Memory by Decreasing Brain O-GlcNAc Cycling in Mouse.

Authors:  Sang-Min Kim; Seungjae Zhang; Jiwon Park; Hyun Jae Sung; Thuy-Duong Thi Tran; ChiHye Chung; Inn-Oc Han
Journal:  Neurotherapeutics       Date:  2021-07-26       Impact factor: 6.088

10.  Repeated hypoxia exposure induces cognitive dysfunction, brain inflammation, and amyloidβ/p-Tau accumulation through reduced brain O-GlcNAcylation in zebrafish.

Authors:  Jiwon Park; Sunhee Jung; Sang-Min Kim; In Young Park; Ngan An Bui; Geum-Sook Hwang; Inn-Oc Han
Journal:  J Cereb Blood Flow Metab       Date:  2021-06-26       Impact factor: 6.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.